🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,180 results for “Takeda Pharmaceuticals International AG” Clear

  1. C1 esterase inhibitor [human] liquid

    Takeda Pharmaceuticals International AG

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  2. CINRYZE 500

    Takeda Pharmaceuticals International AG

    Hereditary Angioedema (HAE)

    phase 3 mab completed

    1 trial

  3. CINRYZE 500 U

    Takeda Pharmaceuticals International AG

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  4. Cabozantinib

    Takeda Pharmaceuticals International AG

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  5. Candesartan

    Takeda Pharmaceuticals International AG

    Heart Failure

    phase 3 small molecule completed

    1 trial

  6. Candesartan Cilexetil

    Takeda Pharmaceuticals International AG

    Stroke

    phase 3 small molecule completed

    1 trial

  7. Candesartan and standard chronic heart disease therapy

    Takeda Pharmaceuticals International AG

    Heart Failure

    phase 3 small molecule terminated

    1 trial

  8. Cinryze®

    Takeda Pharmaceuticals International AG

    Acute Antibody-Mediated Rejection (AMR)

    phase 3 mab terminated

    1 trial

  9. Cohort 1: Lubiprostone Capsule, Fasted

    Takeda Pharmaceuticals International AG

    Healthy Volunteers

    phase 3 small molecule completed

    1 trial

  10. Cx601

    Takeda Pharmaceuticals International AG

    Crohn's Disease

    phase 3 other completed

    3 trials

  11. Cyclobenzaprine HCl

    Takeda Pharmaceuticals International AG

    Neck Pain

    phase 3 small molecule completed

    1 trial

  12. Cyproterone acetate

    Takeda Pharmaceuticals International AG

    Adenocarcinoma, Prostate

    phase 3 small molecule completed

    1 trial

  13. DX-2930

    Takeda Pharmaceuticals International AG

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    3 trials

  14. DX-2930 - 300mg/2wk

    Takeda Pharmaceuticals International AG

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  15. Darvadstrocel

    Takeda Pharmaceuticals International AG

    Complex Perianal Fistulas in Adult Participants With Crohn's Disease

    phase 3 mab completed

    1 trial

  16. Delayed and extended release mesalazine

    Takeda Pharmaceuticals International AG

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  17. Dexlansoprazole

    Takeda Pharmaceuticals International AG

    Gastroesophageal Reflux

    phase 3 small molecule completed

    2 trials

  18. Dexlansoprazole

    Takeda Pharmaceuticals International AG

    Erosive Esophagitis

    phase 3 small molecule terminated

    2 trials

  19. Dexlansoprazole

    Takeda Pharmaceuticals International AG

    Heartburn

    phase 3 small molecule completed

    1 trial

  20. Dexlansoprazole MR

    Takeda Pharmaceuticals International AG

    Esophagitis, Reflux

    phase 3 small molecule completed

    5 trials

  21. Dexlansoprazole MR

    Takeda Pharmaceuticals International AG

    Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    4 trials

  22. Dexlansoprazole MR QD

    Takeda Pharmaceuticals International AG

    Gastroesophageal Reflux

    phase 3 small molecule completed

    1 trial

  23. Doxorubicin

    Takeda Pharmaceuticals International AG

    Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  24. Doxorubicinhydrochlorid Teva® 2 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bleomycin 15000 IU Powder for solution for injection/infusion, Detimedac 200 mg, Pulver zur Herstellung einer Injektions-/Infusionslösung, Doxorubicin hydrochloride 2 mg/ml solution for infusion, ADCETRIS 50 mg powder for concentrate for solution for infusion, Vinblastine Sulfate 1 mg/ml solution for injection, Dacarbazine medac 200 mg, powder for solution for injection/infusion, Vinblastinsulfat Teva® 1 mg/ml Injektions

    Takeda Pharmaceuticals International AG

    Advanced Classical Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources